PDL BioPharma, Inc. Operating Income

Operating Income of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income growth rates and interactive chart. Operating income is the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation, and cost of goods sold (COGS). Operating income–also called income from operations–takes a company's gross income, which is equivalent to total revenue minus COGS, and subtracts all operating expenses. A business's operating expenses are costs incurred from normal operating activities and include items such as office supplies and utilities. Operating income is measured before interest and tax expenses and is a good gauge of a company's operational profitability.


Highlights and Quick Summary

  • Operating Income for the quarter ending June 29, 2020 was $-13.8 Million (a -56.82% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Income decreased by -245.75%
  • Annual Operating Income for 2019 was $-99.8 Million (a 97.28% increase from previous year)
  • Annual Operating Income for 2018 was $-50.6 Million (a -126.11% decrease from previous year)
  • Annual Operating Income for 2017 was $194 Million (a 49.75% increase from previous year)
  • Twelve month Operating Income ending June 29, 2020 was $-128 Million (a 3.65% increase compared to previous quarter)
  • Twelve month trailing Operating Income decreased by -602.54% year-over-year
Trailing Operating Income for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-128 Million $-123 Million $-99.8 Million $25.5 Million
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income of PDL BioPharma, Inc.

Most recent Operating Incomeof PDLI including historical data for past 10 years.

Interactive Chart of Operating Income of PDL BioPharma, Inc.

PDL BioPharma, Inc. Operating Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-13.76 $-31.88
2019 $-91.78 $9.44 $-9.26 $-8.22 $-99.81
2018 $33.5 $36.74 $-125.13 $4.29 $-50.59
2017 $29.87 $32.62 $112.78 $18.51 $193.78
2016 $-7.67 $32.66 $11.14 $93.28 $129.4
2015 $161.53 $116.17 $130.64 $142.04 $550.38
2014 $99.35 $158.91 $155.83 $132.22 $546.31
2013 $107.85 $92.25 $141.74 $84.66 $426.51
2012 $84.67 $79.58 $120.76 $70.4 $355.41
2011 $67.99 $79.81 $118.35 $77.56 $343.7
2010 $-28.43 $75.33 $111.52 $211.08

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.